Indivior Pharmaceuticals (INDV) Common Equity (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Common Equity of -$144.0 million for Q1 2026, up 49.47% year-over-year from -$96.3 million in Q1 2025, and down 46.94% quarter-over-quarter from -$98.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Common Equity (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Common Equity history runs 6 years deep, the most recent figure standing at -$144.0 million for Q1 2026.
- In Q1 2026, Common Equity rose 49.47% year-over-year to -$144.0 million; the TTM figure through Mar 2026 stood at -$144.0 million (up 49.47% YoY), while the FY2025 annual figure was -$98.0 million, up 70.92% from the prior year.
- Common Equity for Q1 2026 stood at -$144.0 million, down from -$98.0 million in the prior quarter.
- The five-year high for Common Equity was -$15.0 million in Q4 2022, with the low at -$337.0 million in Q4 2024.
- The 5-year median for Common Equity is -$207.0 million (2025), against an average of -$207.2 million.
- The sharpest annual moves came in 2023 and 2025: Common Equity sank 1126.67% in 2023, then jumped 70.92% in 2025.
- Indivior Pharmaceuticals' Common Equity stood at -$15.0 million in 2022, then tumbled by 1126.67% to -$184.0 million in 2023, then slumped by 83.15% to -$337.0 million in 2024, then surged by 70.92% to -$98.0 million in 2025, then sank by 46.94% to -$144.0 million in 2026.
- Business Quant data shows INDV's Common Equity at -$144.0 million in Q1 2026, -$98.0 million in Q4 2025, and -$207.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Indivior Pharmaceuticals | 4.53 Bn | 4.31 Bn | 294.00 Mn | -208.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -208.00 Mn |
| Mar 31, 2026 | -144.00 Mn |
| Dec 31, 2025 | -98.00 Mn |
| Sep 30, 2025 | -207.00 Mn |
| Jun 30, 2025 | -257.00 Mn |
| Mar 31, 2025 | -285.00 Mn |
| Dec 31, 2024 | -337.00 Mn |
| Sep 30, 2024 | -310.00 Mn |
| Jun 30, 2024 | -281.00 Mn |
| Mar 31, 2024 | -161.00 Mn |
| Dec 31, 2023 | -184.00 Mn |
| Dec 31, 2022 | -15.00 Mn |
| Dec 31, 2021 | 121.00 Mn |